Health Condition 1: F20- Schizophrenia
Conditions
Interventions
Intervention1: Adjunctive Zinc Therapy: Capsules zinc sulphate 100mg OD orally for 6 weeks in patients with schizophrenia along with usual treatment
Control Intervention1: Placebo: Capsule Placebo OD
Sponsors
Central Institute of psychiatry
Eligibility
Inclusion criteria
Inclusion criteria: 1.Male and female inpatients satisfying the ICD 10 - DCR [1993] criteria of Schizophrenia 2.Age group of 18-60 years. 3.Illness duration of minimum 2 years. 4.PANSS total score of minimum 80. 5.Those who give informed consent for participating in the study.
Exclusion criteria
Exclusion criteria: 1.Any other major comorbid psychiatric diagnosis and substance dependence excluding nicotine & caffeine. 2.Significant current/ past medical or neurological illness including severe hepatic disease and history of severe head injury. 3.Known hypersensitivity to Cap. Zinc Sulphate or any of its components. 4.Patients who had received ECT in the last 6 months. 5.Comorbid medical illness known to affect zinc levels including acute or chronic inflammatory disorder and neurological disorder. 6.Patient on multivitamin supplementation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effectiveness of Cap. zinc sulphate (100mg/day) as an adjunctive therapy assessed by PANSS and CGI scores in patients with schizophreniaTimepoint: Baseline, 2 weeks and 6 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in the levels of serum zinc, NF-kB and IL-6 in patients receiving adjunctive Cap. Zinc sulphate(100mg/day)Timepoint: Baseline, 2 weeks and 6 weeks | — |
Countries
India
Contacts
Public ContactDr Roshan V Khanande
Central institute of psychiatry
Outcome results
None listed